You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Though it is unclear whether the virus became pathogenic before or after the jump from animals to humans, genomic features point to a natural source for the COVID-19 coronavirus.
The New York Times reports on how an international team of researchers is working to find drugs that may affect how SARS-CoV-2 interacts with host proteins.
The test from Singapore-based Credo requires minimal training to run and can detect pathogens in 20 minutes, with about one minute of hands-on time.
In PNAS this week: comparative genomic analysis to find Pseudomonas aeruginosa virulence genes, "anti-CRISPR" proteins in Staphylococcus aureus, and more.
The testing products, developed by China-based 3D Medicines, have received CE marking and approval from the Chinese National Medical Products Administration, Todos said.
The Trump Administration may have offered a German biopharmaceutical firm a large sum of money for the exclusive right to a vaccine, the Guardian reports.
ScienceInsider reports on how the COVID-19 pandemic is affecting research activity across the world.
In PLOS this week: computational strategy to study human population histories, BRAF mutational load in melanoma and disease progression, and more.
The firms have entered into a strategic partnership to integrate their respective amplicon-based target enrichment technologies for use in NGS testing.
According to the recall, initiated on Jan. 28, a glitch in the software’s data reporting to LIM systems could cause false-negative results from PCR assays running on the instrument.
A German shepherd called Nala has had her genome sequenced.
A coronavirus serology test garners Emergency Use Authorization from the US Food and Drug Administration, but the Los Angeles Times asks: how will tests like that be used?
Certain gene variants in conjunction with a healthy lifestyle may keep brains young, according to New Scientist.
In Science this week: increased CD8 T cell density and increased IFN-gamma response may indicate metastatic prostate cancer patients who will respond to immune checkpoint blockade therapy.